Synonym
NEt-3IP; NEt3IP; NEt 3IP;
IUPAC/Chemical Name
4-(ethyl(3-isopropoxy-4-isopropylphenyl)amino)benzoic acid
InChi Key
NHPGPVYPYBWTBU-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H27NO3/c1-6-22(17-9-7-16(8-10-17)21(23)24)18-11-12-19(14(2)3)20(13-18)25-15(4)5/h7-15H,6H2,1-5H3,(H,23,24)
SMILES Code
CC(C)C1=C(OC(C)C)C=C(N(CC)C2=CC=C(C(O)=O)C=C2)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
341.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yamamoto A, Kakuta H, Sugimoto Y. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator- activated receptor γ agonist in mice. Int Immunopharmacol. 2014 Sep;22(1):204-8. doi: 10.1016/j.intimp.2014.06.028. Epub 2014 Jun 27. PMID: 24975659.
2: Kakuta H, Ohsawa F, Yamada S, Makishima M, Tai A, Yasui H, Yoshikawa Y. Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice. Biol Pharm Bull. 2012;35(4):629-33. doi: 10.1248/bpb.35.629. PMID: 22466572.
3: Yamamoto A, Kakuta H, Miyachi H, Sugimoto Y. Involvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In Vivo. PPAR Res. 2011;2011:840194. doi: 10.1155/2011/840194. Epub 2011 Dec 11. PMID: 22190910; PMCID: PMC3236425.
4: Kakuta H. [Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor]. Yakugaku Zasshi. 2011;131(6):917-23. Japanese. doi: 10.1248/yakushi.131.917. PMID: 21628978.
5: Ogasawara A, Murakami Y, Yakushiji N, Ohsawa F, Kusaba J, Aiba T, Kurosaki Y, Kakuta H. Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats. Drug Dev Ind Pharm. 2011 Sep;37(9):1060-7. doi: 10.3109/03639045.2011.559247. Epub 2011 Mar 21. PMID: 21417609.
6: Ohsawa F, Morishita K, Yamada S, Makishima M, Kakuta H. Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers. ACS Med Chem Lett. 2010 Aug 27;1(9):521-5. doi: 10.1021/ml100184k. PMID: 24900241; PMCID: PMC4007838.
7: Takamatsu K, Takano A, Yakushiji N, Morohashi K, Morishita K, Matsuura N, Makishima M, Tai A, Sasaki K, Kakuta H. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist). ChemMedChem. 2008 May;3(5):780-7. doi: 10.1002/cmdc.200700313. PMID: 18297677.
